KalVista announces Q3 EPS of 92 cents, compared to 84 cents in the previous year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy KALV?
Launch Progress: The US launch of EKTERLY is gaining momentum due to strong early demand and rapid adoption among physicians and patients with hereditary angioedema (HAE).
Global Expansion: EKTERLY has recently been launched in Germany and received approval in Australia, marking five total regulatory approvals as the company aims for a global presence.
Financial Resources: KalVista has successfully closed a $144 million convertible note offering, providing the financial means to support its global launch strategy and long-term growth.
Market Confidence: There is a consistent increase in new patient starts and repeat prescriptions, indicating sustained confidence in EKTERLY's clinical value as the first oral on-demand treatment for HAE.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.950
Low
29.00
Averages
34.38
High
39.00
Current: 18.950
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KALVISTA PHARMACEUTICALS INC: STIFEL INCREASES TARGET PRICE FROM $39 TO $42
- Price Increase Announcement: Stifel has raised the price target for KalVista Pharmaceuticals from $39 to $42.
- Market Implications: This adjustment reflects Stifel's updated outlook on KalVista's performance and potential in the pharmaceutical market.
See More
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
KalVista Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: KalVista Pharmaceuticals reported a Q4 GAAP EPS of -$2.03, which may not be directly comparable to estimates, but revenue of $49.08 million exceeded expectations by $16.79 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company had approximately $300.2 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the next few years and supporting its strategy towards profitability.
- EKTERLY Sales Outlook: The anticipated cash reserves and projected revenues from EKTERLY sales are expected to fund the company through to profitability, reflecting confidence in the product's market potential.
- Future Growth Strategy: KalVista Pharmaceuticals aims to drive the next stage of growth by expanding EKTERLY's pediatric label, a strategy that not only broadens market coverage but could significantly enhance the company's future revenue potential.
See More
KALVISTA PHARMACEUTICALS INC REPORTS $49.1 MILLION IN NET PRODUCT REVENUE FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
- Company Overview: Kalvista Pharmaceuticals has reported a net product revenue of $49.1 million for the eight-month period ending December 31, 2025.
- Financial Performance: The revenue figure indicates the company's performance in the pharmaceutical market during the specified timeframe.
See More
KALVISTA PHARMACEUTICALS INC: STIFEL INCREASES TARGET PRICE FROM $39 TO $42
- Price Increase Announcement: Stifel has raised the price target for KalVista Pharmaceuticals from $39 to $42.
- Market Implications: This adjustment reflects Stifel's updated outlook on KalVista's performance and potential in the pharmaceutical market.
See More
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
KalVista Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: KalVista Pharmaceuticals reported a Q4 GAAP EPS of -$2.03, which may not be directly comparable to estimates, but revenue of $49.08 million exceeded expectations by $16.79 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company had approximately $300.2 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the next few years and supporting its strategy towards profitability.
- EKTERLY Sales Outlook: The anticipated cash reserves and projected revenues from EKTERLY sales are expected to fund the company through to profitability, reflecting confidence in the product's market potential.
- Future Growth Strategy: KalVista Pharmaceuticals aims to drive the next stage of growth by expanding EKTERLY's pediatric label, a strategy that not only broadens market coverage but could significantly enhance the company's future revenue potential.
See More
KALVISTA PHARMACEUTICALS INC REPORTS $49.1 MILLION IN NET PRODUCT REVENUE FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
- Company Overview: Kalvista Pharmaceuticals has reported a net product revenue of $49.1 million for the eight-month period ending December 31, 2025.
- Financial Performance: The revenue figure indicates the company's performance in the pharmaceutical market during the specified timeframe.
See More
